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Summary. Background: A reduced sensitivity for activated
protein C (APC) is associated with an increased risk of venous
thrombosis even in the absence of the factor (F)V Leiden
mutation. This risk has been demonstrated with two APC
sensitivity tests, which quantify the eﬀects of APC on the
activated partial thromboplastin time (APTT) and the endog-
enous thrombin potential (ETP), respectively.Objectives: We
examined determinants of both APC sensitivity tests in the
control group of the Leiden Thrombophilia Study (LETS).
Methods: Multiple linear regression analysis was performed
with normalized APC-SRAPTT or APC-SRETP as dependent
variable and putative determinants [levels of FII, FV, FVII,
FVIII,FIX,FX,FXI,FXII,FXIIIA subunit, FXIIIB subunit,
protein S total, protein S free, protein C, tissue factor pathway
inhibitor (TFPI) total, TFPI free, antithrombin and ﬁbrinogen]
as independent variables. Results and conclusions: The major
determinant of the APTT-based test was FVIII level, followed
by FII level. The ETP-based test was inﬂuenced most by free
protein S and free TFPI levels. In both tests FXa formation
plays a major role, as the eﬀect of FVIII and TFPI on the tests
seems to be executed via FXa. The ETP-based test was also
strongly inﬂuenced by oral contraceptive use, even when we
adjusted for all the clotting factors listed above. Thismeans that
the eﬀect of oral contraceptives on the ETP-based test is not
fully explained by the changes of coagulation factor levels
investigated in this study, and that the molecular basis of
acquired APC resistance during use of oral contraceptives
remains to be established.
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Introduction
Activated protein C (APC), in combination with its cofactor
protein S, acts as an anticoagulant by inactivating the activated
cofactors factor (F)Va and FVIIIa by speciﬁc peptide bond
cleavages. Factor V acts together with protein S as a cofactor of
APC in the inactivation of activated FVIII. In 1993, Dahlba¨ck
et al. reported a new mechanism for thrombophilia, charac-
terized by a poor anticoagulant response of plasma to APC [1].
Most cases of this so-called APC resistance are caused by a
mutation in one of the APC cleavage sites (Arg506) of FV (FV
Leiden) [2]. This mutation is a common risk factor for venous
thrombosis.
Several methods for the detection of APC resistance have
been developed. The original test of Dahlba¨ck et al. evaluates
the increase of the activated partial thromboplastin time
(APTT) after addition of a ﬁxed amount of APC to plasma [1].
Reduced prolongation of the APTT indicates resistance to the
anticoagulant action of APC. The sensitivity and speciﬁcity for
the FV Leiden mutation is dependent on the APTT reagent
used [3]. A disadvantage of the APTT-based test is that it
cannot be used in patients using oral anticoagulants or with
lupus anticoagulants, because of their prolonged baseline
APTT.
Rosing and co-workers developed an APC sensitivity test
which is based on quantiﬁcation of the effect of APC on the
endogenous thrombin potential (ETP), i.e. on the time integral
of thrombin generated in plasma in which coagulation is
initiated via the extrinsic pathway [4,5].
In addition to the above-mentioned APTT- and ETP-based
tests several other APC sensitivity tests were developed based
on the prolongation by APC of the prothrombin time, the FXa
clotting time, the Russell Viper venom time, or the textarin
time. Also modiﬁed tests, in which patient plasma is diluted in
FV-deﬁcient plasma, have been developed which have a high
sensitivity and speciﬁcity for the FV Leiden mutation also in
patients using oral anticoagulants and in patients with lupus
anticoagulants. A disadvantage of these latter tests is that they
cannot detect a reduced sensitivity for APC in the absence of
FV Leiden.
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It has been demonstrated with both the APTT- and the
ETP-based APC sensitivity test that a reduced sensitivity for
APC not because of FV Leiden also increases the risk of
venous thrombosis [6–8]. Causes of such a reduced response
to APC are for instance pregnancy, oral contraceptive use,
hormone replacement therapy, lupus anticoagulants, and
high FVIII levels. The detection of these acquired APC-
resistant phenotypes depends on the test that is used, e.g. in
the ETP-based test plasma of women using oral contracep-
tives appeared to be considerably APC-resistant [9], while in
the APTT-based test FVIII levels seemed to be a major
determinant [6,10]. So, the APTT- and the ETP-based APC
sensitivity tests are both global tests that can predict
thrombosis risk [6–8], but they seem to have different
determinants. The aim of this study was to examine
extensively the determinants of the APTT- and ETP-based
APC sensitivity tests. Knowledge of the main determinants
may help us understand the mechanisms leading to APC
resistance. For our investigation we used a large group
of individuals without a history of venous thrombosis
(the control group of the Leiden Thrombophilia Study,
LETS).
Patients and methods
Subjects
The investigated subjects were 474 individuals (202 men and
272 women) without a personal history of thrombosis from
a population-based case–control study on venous thrombosis
(LETS) [11]. For the present investigation all subjects with
the FV Leiden mutation were excluded (n ¼ 14). Further-
more, analysis was restricted to subjects in which all
investigated parameters [FII, FV, FVII, FVIII, FIX,
FX, FXI, FXII, FXIII A and B subunit, protein S total,
protein S free, protein C, tissue factor pathway inhibitor
(TFPI) free, TFPI total, antithrombin, ﬁbrinogen, normal-
ized APC-SRAPTT and normalized APC-SRETP] were meas-
ured. Therefore, we excluded 47 subjects without free
protein S data, one subject with missing TFPI data, four
subjects with missing normalized APC-SRAPTT, and one
subject who used oral anticoagulants and had missing free
protein S and normalized APC-SRAPTT data. This selection
resulted in 407 subjects available for analysis (166 men and
241 women with a mean age of 46 years; range: 16–73). For
analyses concerning oral contraceptive use 391 subjects (166
men, 53 women using oral contraceptives and 172 women
not using oral contraceptives) were used, because oral
contraceptive use was unknown for 16 women.
Blood collection of LETS samples
Blood was collected into tubes containing 0.1 volume of
0.106 M trisodium citrate. Plasma was prepared by centrifuga-
tion for 10 min at 2000 g at room temperature and stored at
)70 C.
APTT-based APC sensitivity test
The sensitivity of the plasma APTT to APC was measured in
Leiden as described before with Cephotest (Nycomed
Pharma, Oslo, Norway) as activator [11,12]. Because this
APTT reagent contains a high concentration of phospholipids,
the test is not inﬂuenced by the presence of residual platelets in
plasma. The APC sensitivity ratio (APC-SRAPTT) is deﬁned as
the APTT in the presence of APC divided by the APTT in the
absence of APC. To reduce between-assay variation results are
expressed as normalized APC sensitivity ratios (n-APC-
SRAPTT). The normalized APC-SRAPTT is calculated by
dividing the APC-SRAPTT of the sample by the APC-SRAPTT
of pooled normal plasma, which is measured in the same run.
The pooled normal plasma was prepared in the same way as
plasma of the LETS samples.
ETP-based APC sensitivity test
The sensitivity of the plasma ETP to APC was measured in
Maastricht as described before [8,9]. Under these conditions the
test is insensitive for small amounts of phospholipid present in
plasma [13]. The normalized APC-SRETP is deﬁned as the ratio
of a2-macroglobulin-thrombin (a2M-IIa) determined in the
presence and absence of APC divided by the same ratio
determined in pooled normal plasma. The pooled normal
plasma used for the ETP-based test was obtained using 0.1
volume of 0.13 M trisodium citrate as anticoagulant [9].
Determination of coagulation parameters
Measurements of FII activity [14], FV ag [15], FVII activity
[16], FVIII activity [17], FIX ag [18], FX ag [19], FXI ag [20],
FXII activity [21], FXIII A and B subunit ag [22], protein C
activity [23], total protein S ag [23], free protein S ag [23], free
TFPI ag [24], total TFPI ag [24], antithrombin activity [23], and
ﬁbrinogen levels [16] have been described before. The above-
mentioned parameters were all expressed in U dL)1, except
ﬁbrinogen levels that were expressed in g L)1 and free and total
TFPI levels that were expressed in ng mL)1. By deﬁnition
1 mL pooled normal plasma contains 1 unit.
Statistical analysis
To assess putative determinants of the normalized APC-SR
multiple linear regression analysis was performed with nor-
malized APC-SRAPTT or APC-SRETP as dependent variable
and the determinants (levels of FII, FV, FVII, FVIII, FIX, FX,
FXI, FXII, FXIII A subunit, FXIII B subunit, protein S total,
protein S free, protein C, TFPI total, TFPI free, antithrombin
and ﬁbrinogen) as independent variables (model 1, n ¼ 407).
The range and distribution of coagulation factor levels and
normalized APC-SRAPTT andAPC-SRETP differs. To facilitate
comparison of the two tests all variables (normalized APC-SRs
and coagulation factors) were expressed as standardized values
(Z scores). Multiple linear regression analysis was performed
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with these standardized values. The resulting standardized
regression coefﬁcient b for a coagulation factor indicates the
increase of the normalized APC-SR (expressed in SD) when
that particular coagulation factor increases with 1 SD and all
other variables in the model are unchanged. To investigate the
inﬂuence of sex, age, and oral contraceptive use, multiple linear
regression analysis was performed with age (standardized), sex
(0 ¼ male, 1 ¼ female), and oral contraceptive use at vene-
puncture (0 ¼ no, 1 ¼ yes) as additional independent variables
(model 2, n ¼ 391). In this model, the regression coefﬁcient for
a dichotomized variable (e.g. sex) indicates the average increase
of the normalized APC-SR (in SD) for a particular subgroup
(e.g. women) compared with another subgroup (e.g. men).
Results
In Fig. 1 the normalized APC-SRETP is plotted against the
normalized APC-SRAPTT. Because APC inhibits thrombin
formation and prolongs the APTT, plasmas with a reduced
sensitivity for APCwill give a decrease of the normalized APC-
SR in the APTT-based test and an increase in the ETP-based
test. The two normalized ratios were associated, but there was
considerable variation (regression coefﬁcient b ¼ )4.9; 95%
CI: )6.1 to )3.6). In Table 1, the mean normalized APC ratios
for the two tests are shown for the whole population and
stratiﬁed for sex and oral contraceptive use.
Results of the two APC sensitivity tests in the complete
population-based case–control study have been described
elsewhere [6,8]. The main purpose of the present study was to
assess determinants of both tests by a multiple linear regression
model. In this model (model 1, Table 2) the main determinant
of the APTT-based test appeared to be FVIII level (standard-
ized regression coefﬁcient b ¼ )0.55) followed by FII (pro-
thrombin) level (b ¼ )0.25). The ETP-based test was
inﬂuenced most by free TFPI (b ¼ )0.39) and free protein S
levels (b ¼ )0.33). Addition of sex, age, and oral contraceptive
use to the model (model 2, Table 3), only resulted in marginal
changes in the effect of the coagulation factors on the APTT-
based test. The regression coefﬁcients for the two most
important determinants, FVIII (b ¼ )0.52) and FII level
(b ¼ )0.23), hardly changed with this adjustment. However,
adjustment for sex, age, and oral contraceptive use reduced the
effects of the major determinants of the ETP-based test,
namely free TFPI level (b ¼ )0.25) and free protein S level
(b ¼ )0.26). Oral contraceptive use appeared to be a strong
determinant of the ETP-based test. Even after adjustment for
many coagulation factors (model 2), oral contraceptive use led
to an average increase of the normalized APC-SRETP with 0.78
SD. The inﬂuence of oral contraceptive use on theAPTT-based
test was less (b ¼ )0.21). In both tests women had a reduced
sensitivity for APC compared with men. Sex had a larger effect
on the ETP-based test (b ¼ 0.44) than on the APTT-based test
(b ¼ )0.24). There was no inﬂuence of age (SD: 13.3) on the
ETP-based test and only a small effect on the APTT-based test
(b ¼ )0.13).
Because an APC sensitivity test is a global test, it is not
surprising that the test is inﬂuenced by many of the examined
variables. We examined more closely the coagulation param-
eters with the strongest effect on the two tests, i.e. levels of FII,
FVIII, free protein S, and free TFPI. These four variables were
stratiﬁed into quartiles and for each quartile the mean
normalized APC-SRAPTT and the mean normalized APC-
SRETP were calculated (Table 4). When FVIII levels increase,
the mean normalized APC-SRAPTT decreases, while such a
clear trend was not observed for the normalized APC-SRETP.
A similar trend, but weaker, was seen for FII levels. In contrast,
free protein S levels and free TFPI levels show an association
with the normalized APC-SRETP and not with the normalized
APC-SRAPTT.
Discussion
A reduced sensitivity for APC, as measured with the APTT- or
the ETP-based APC sensitivity test, is associated with an
increased risk of venous thrombosis both in the absence and
presence of FV Leiden [6,8,11]. In this study we found that
many coagulation factors have an effect on these global tests,
with the APTT-based APC sensitivity test mainly inﬂuenced by
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Fig. 1. Normalized activated protein C (APC)-SRETP vs. normalized
APC-SRAPTT. Regression line: n-APC-SRETP ¼ 7.3 ) 4.9 · n-APC-
SRAPTT.
Table 1 Mean APC sensitivity in healthy individuals
n
n-APC-SRAPTT
(95% CI)
n-APC-SRETP
(95% CI)
All 407 1.02 (1.01–1.03) 2.33 (2.18–2.48)
Sex
Men 166 1.05 (1.04–1.07) 1.38 (1.27–1.49)
Women 241 0.99 (0.98–1.00) 2.99 (2.78–3.19)
Use of oral contraceptives*
Yes 53 0.94 (0.92–0.96) 4.88 (4.44–5.32)
No 172 1.00 (0.99–1.02) 2.43 (2.26–2.61)
*Oral contraceptive use at venepuncture was unknown for 16 women.
APC, activated protein C; APTT, activated partial thromboplastin
time; CI, conﬁdence interval.
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FVIII levels and the ETP-based test by free TFPI and free
protein S levels. The latter test was also highly dependent on
oral contraceptive use.
We found that increased FII (prothrombin) levels reduced
the sensitivity for APC in the APTT-based test. In a model
system containing puriﬁed proteins it has been demonstrated
before that prothrombin inhibits the ability of APC to
inactivate FVa [25]. Furthermore, it has been shown in a
group of 285 normal subjects that hyperprothrombinemia may
Table 2 Mean change in normalized APC-SR (SD*) with 1 SD increase in coagulation factor (model 1)
SD
b (95% CI)
APTT-based test ETP-based test
Factor II 15.0 )0.25 ()0.33 to )0.18) 0.15 (0.07–0.23)
Factor V 31.8 0.15 (0.07–0.22) )0.14 ()0.21 to )0.06)
Factor VII 21.7 )0.09 ()0.17 to )0.02) 0.10 (0.03–0.18)
Factor VIII 32.5 )0.55 ()0.62 to )0.48) 0.05 ()0.02 to 0.12)
Factor IX 19.8 )0.12 ()0.21 to )0.04) 0.20 (0.11–0.28)
Factor X 16.8 )0.12 (0.21 to )0.04) 0.11 (0.02–0.19)
Factor XI 19.5 )0.07 ()0.14 to )0.001) 0.06 ()0.01 to 0.13)
Factor XII 28.4 0.08 (0.01–0.15) 0.02 ()0.06 to 0.09)
Factor XIII A 23.7 0.03 ()0.07 to 0.13) 0 ()0.10 to 0.10)
Factor XIII B 18.5 0.01 ()0.10 to 0.12) 0.02 ()0.09 to 0.13)
Protein S total 19.7 0.01 ()0.08 to 0.11) )0.18 ()0.27 to )0.09)
Protein S free 20.5 0.10 (0.01–0.19) )0.33 ()0.42 to )0.23)
Protein C 18.1 )0.15 ()0.22 to )0.07) 0.02 ()0.06 to 0.10)
TFPI total 15.1 )0.02 ()0.11 to 0.07) )0.03 ()0.12 to 0.06)
TFPI free 4.81 0.13 (0.03–0.22) )0.39 ()0.49 to )0.30)
Antithrombin 10.5 0.02 ()0.05 to 0.09) )0.07 ()0.15 to )0.01)
Fibrinogen 0.65 0.07 ()0.01 to 0.16) )0.03 ()0.11 to 0.06)
Standardized regression coeﬃcients b were obtained with multivariate linear regression analysis.
*Standard deviation n-APC-SRAPTT ¼ 0.11 and standard deviation n-APC-SRETP ¼ 1.54.
APC, activated protein C; CI, conﬁdence interval; APTT, activated partial thromboplastin time; ETP, endogenous thrombin potential; TFPI,
tissue factor pathway inhibitor.
Table 3 Multiple linear regression including age, sex, and oral contra-
ceptive use (model 2)
b (95% CI)
APTT-based test ETP-based test
Factor II )0.23 ()0.31 to )0.15) 0.07 ()0.001 to 0.15)
Factor V 0.13 (0.06–0.21) )0.11 ()0.17 to )0.04)
Factor VII )0.07 ()0.15 to 0.01) 0.07 (0.001–0.14)
Factor VIII )0.52 ()0.60 to )0.45) 0.04 ()0.03 to 0.11)
Factor IX )0.11 ()0.20 to )0.03) 0.16 (0.08–0.24)
Factor X )0.15 ()0.24 to )0.05) 0.03 ()0.05 to 0.12)
Factor XI )0.04 ()0.12 to 0.03) 0.03 ()0.03 to 0.10)
Factor XII 0.09 (0.02–0.17) )0.03 ()0.10 to 0.04)
Factor XIII A 0.05 ()0.05 to 0.16) )0.02 ()0.12 to 0.07)
Factor XIII B )0.01 ()0.12 to 0.11) 0.06 ()0.05 to 0.16)
Protein S total 0.01 ()0.09 to 0.11) )0.09 ()0.18 to 0.01)
Protein S free 0.09 ()0.01 to 0.18) )0.26 ()0.35 to )0.17)
Protein C )0.13 ()0.21 to )0.05) )0.01 ()0.08 to 0.07)
TFPI total )0.02 ()0.11 to 0.07) 0.02 ()0.06 to 0.11)
TFPI free 0.09 ()0.01 to 0.19) )0.25 ()0.34 to )0.15)
Antithrombin )0.01 ()0.09 to 0.06) )0.05 ()0.12 to 0.02)
Fibrinogen 0.10 (0.01–0.18) )0.05 ()0.12 to 0.03)
Age )0.13 ()0.21 to )0.04) )0.04 ()0.12 to 0.04)
Sex* )0.24 ()0.39 to )0.08) 0.44 (0.29–0.59)
Oral contraceptive
use
)0.21 ()0.51 to 0.10) 0.78 (0.50–1.07)
Standardized regression coeﬃcients b were obtained with multivariate
linear regression analysis.
*0 ¼ male and 1 ¼ female.
0 ¼ no and 1 ¼ yes.
CI, conﬁdence interval; APTT, activated partial thromboplastin time;
TFPI, tissue factor pathway inhibitor; ETP, endogenous thrombin
potential.
Table 4 Mean normalized APC-SRAPTT and mean normalized APC-
SRETP for quartiles of factor II, factor VIII, protein S free, and TFPI free
Number of
subjects
Mean
n-APC-SRAPTT
(95% CI)
Mean
n-APC-SRETP
(95% CI)
Factor II (U dL)1)
<94 99 1.07 (1.05–1.09) 2.21 (1.94–2.47)
94–103 106 1.03 (1.01–1.06) 2.21 (1.93–2.49)
103–113 97 1.01 (0.99–1.04) 2.57 (2.17–2.97)
>113 105 0.96 (0.94–0.97) 2.36 (2.10–2.62)
Factor VIII (U dL)1)
<99 101 1.11 (1.09–1.14) 2.11 (1.89–2.34)
99–119 105 1.03 (1.02–1.05) 2.39 (2.06–2.73)
119–143 99 0.99 (0.98–1.01) 2.32 (2.01–2.63)
>143 102 0.93 (0.92–0.94) 2.50 (2.18–2.83)
Protein S free (U dL)1)
<83 99 1.02 (1.00–1.05) 3.34 (2.98–3.71)
83–96 104 1.03 (1.01–1.06) 2.54 (2.25–2.83)
96–111 99 1.02 (1.00–1.04) 1.82 (1.61–2.03)
>111 105 1.00 (0.98–1.02) 1.66 (1.45–1.87)
TFPI free (ng mL)1)
<9.5 101 0.99 (0.97–1.01) 3.96 (3.63–4.30)
9.5–12.5 102 1.05 (1.02–1.07) 2.24 (2.02–2.46)
12.5–15.3 102 1.02 (1.00–1.03) 1.84 (1.67–2.02)
>15.3 102 1.02 (1.00–1.04) 1.31 (1.15–1.46)
APC, activated protein C; APTT, activated partial thromboplastin
time; ETP, endogenous thrombin potential; TFPI, tissue factor path-
way inhibitor; CI, conﬁdence interval.
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lead to APC resistance [26]. By diluting normal plasma in FII-
deﬁcient plasma de Ronde and Bertina previously demonstra-
ted that a reduction in prothrombin level leads to an increased
sensitivity for APC in the APTT-based test [12]. Castaman
et al. obtained the same results by adding puriﬁed prothrombin
to normal plasma [27]. In the same study, the response to APC
was assessed in families with the prothrombin 20210A
variation, which is associated with increased prothrombin
levels [14]. A reduced sensitivity for APC was found in 20210A
heterozygotes compared with wild-type carriers [27]. All these
studies suggest that FII levels inﬂuence the APTT-based APC
sensitivity test. Our results show, however, that this effect is
moderate and weaker than the observed effect of FVIII levels
on the APTT-based test.
A reduction in sensitivity for APC at increased FVIII levels
was demonstrated earlier both with our local APTT-based
APC sensitivity test (with Cephotest as activator) [6] and with
a commercial APTT-based APC sensitivity test (Coatest
APCTM Resistance, Chromogenix, Milan, Italy) [10,28]. No
signiﬁcant effect of FVIII was observed in the ETP-based test,
although the data in Table 4 suggest that FVIII levels may
have a minor effect on the normalized APC-SRETP. The
insensitivity of the ETP-based test for FVIII levels is probably
due to the high tissue factor concentration present in the ETP
test used in this study. Lowering the tissue factor concentration
probably will make thrombin generation more dependent on
the concentration of the components of the tenase complex
(FIX, FVIII) [29]. It will be of interest to see whether reduction
of the tissue factor concentration will result in a higher
sensitivity of the ETP-based test for FVIII levels.
The fact that the APTT-based test is greatly inﬂuenced by
FVIII levels suggests that FXa formation plays an important
role in this test. An increase in FVIII level will lead to increased
activation of FX. Increased FXa formation can result in a
reduced sensitivity for APC, as it was shown that FXa protects
FVa from inactivation by APC [30–34] by selectively blocking
cleavage at Arg506 [35], which results in slow inactivation of
FVa via APC-mediated cleavage at Arg306 [36–38]. FXa
formation also seems to be important in the ETP-based test.
Namely, in agreement with previous ﬁndings [39], we found
that the latter test is inﬂuenced by free TFPI levels, with a
reduction in free TFPI level leading to a reduced sensitivity for
APC. TFPI is an inhibitor that regulates the extrinsic (tissue
factor-induced) coagulation pathway. TFPI inhibits FXa and
the FXa/TFPI complex is a potent inhibitor of the tissue factor/
FVIIa complex (for a review see Ref. [40]). When free TFPI
levels are reduced this will lead to an initial increase in FXa
formation, which, by the above-mentioned mechanism (i.e.
protection at Arg506) [35], might result in a reduced sensitivity
for APC. Curvers et al. [13] demonstrated that the efﬁcacy by
which APC inhibits thrombin formation in the ETP-based test
is decreased at high tissue factor concentrations [13]. In view of
this observation it is not surprising that the ETP-based test is
inﬂuenced by free TFPI levels.
We conﬁrmed that a reduction in free protein S level leads to
a reduced sensitivity in the ETP-based APC sensitivity test
[39,41,42]. In contrast, de Ronde and Bertina showed before by
diluting normal plasma in protein S-deﬁcient plasma that the
APTT-based test is only affected by very low protein S levels
(<20 U dL)1) [12]. Protein S is a cofactor of APC, which
speciﬁcally accelerates APC-mediated cleavage at Arg306 of
FVa [35]. A reduced protein S level will lead to a reduced
cleavage of FVa at Arg306 by APC, resulting in a delayed FVa
inactivation and in increased thrombin formation. The fact
that the ETP-based test is affected by protein S level whereas
the APTT-based test is not, might suggest that the Arg306
cleavage is more important in the ETP-based test than in the
APTT-based test.
The APTT-based APC sensitivity test was only moderately
inﬂuenced by sex and oral contraceptive use, while the ETP-
based test was strongly affected by these variables. In the latter
test women have a reduced response to APC compared with
men and oral contraceptive users have the lowest response.
This effect cannot be explained by a reduction of protein S
levels in oral contraceptive users, because in our study
population free protein S levels were not materially different
in women using oral contraceptives compared with non-users
[43,44]. Furthermore, addition of oral contraceptive use to the
multiple regression model (model 2) only slightly reduced the
effect of free protein S on the test. Part of the effect of oral
contraceptives on theAPC responsemay be executed via TFPI.
It has been reported that women taking oral contraceptives
have reduced TFPI levels [45] and we showed here that
adjustment for oral contraceptive use reduced the inﬂuence of
free TFPI level on the test. Initiation of coagulation occurs in
the case of the APTT via the intrinsic pathway and in the case
of the ETP via the extrinsic pathway (tissue factor/FVIIa). This
indicates that the basis of the impaired APC response in
women using oral contraceptives may be sought in the activity
or regulation of the extrinsic pathway. Because oral contra-
ceptive use affects the concentrations of many proteins
involved in blood coagulation [46] a combination of these
effects will most likely lead to a reduced sensitivity for APC.
However, in our analysis a strong effect of oral contraceptive
use on the ETP-based test persisted (b ¼ 0.78) when several
coagulation factors were taken into account (model 2). This
means that the effect of oral contraceptives on the ETP-based
test is mediated by variables (e.g. coagulation factors or other
plasma components) that were not included in our analysis.
Also the differences in APC sensitivity between men and
women in both the ETP-based and the APTT-based test are
not fully explained by the other variables in the model,
because an effect of sex (b ¼ )0.24 for the APTT-based test
and b ¼ 0.44 for the ETP-based test) on the APC sensitivity
still exists (model 2).
We observed a moderate correlation between the APC
sensitivity measured with the APTT-based test and the
sensitivity measured with the ETP-based test (see Fig. 1). It is
therefore good to realize that a person who is typed APC-
resistant’ in the ETP-based test will not by deﬁnition be APC-
resistant in the APTT-based test. The two global tests evaluate
APC resistance via different pathways. It will be of interest to
1492 M. C. H. de Visser et al
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investigate whether it is possible to design a test, which is
sensitive for FVIII and prothrombin as well as free protein S,
and free TFPI.
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